Ischemia reperfusion-induced metastasis is resistant to PPARγ agonist pioglitazone in a murine model of colon cancer

[1]  N. Yamamoto,et al.  Pioglitazone, an agonist of PPARγ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Jiahong Dong,et al.  PPARγ activation reduces ischemia/reperfusion-induced metastasis in a murine model of hepatocellular carcinoma , 2015, Experimental and therapeutic medicine.

[3]  R. Hoffman,et al.  A Color-coded Imageable Syngeneic Mouse Model of Stromal-cell Recruitment by Metastatic Lymphoma. , 2015, Anticancer research.

[4]  B. Lévy,et al.  Hepatic ischemia-reperfusion increases circulating bone marrow-derived progenitor cells and tumor growth in a mouse model of colorectal liver metastases. , 2013, The Journal of surgical research.

[5]  J. Belghiti,et al.  Oncologic Resection for Malignant Tumors of the Liver , 2011, Annals of surgery.

[6]  H. Spiegel,et al.  Hepatic ischaemia–reperfusion injury from bench to bedside , 2010, The British journal of surgery.

[7]  Jong-Wook Park,et al.  PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. , 2009, Biochemical and biophysical research communications.

[8]  T. Kubota,et al.  Pioglitazone, a ligand for peroxisome proliferator-activated receptor-gamma acts as an inhibitor of colon cancer liver metastasis. , 2008, Anticancer research.

[9]  Jun Suk Kim,et al.  PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo , 2008, Investigational New Drugs.

[10]  M. Sho,et al.  Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. , 2007, Journal of hepatology.

[11]  Meng Yang,et al.  Whole-body subcellular multicolor imaging of tumor-host interaction and drug response in real time. , 2007, Cancer research.

[12]  Meng Yang,et al.  In vivo color-coded imaging of the interaction of colon cancer cells and splenocytes in the formation of liver metastases. , 2006, Cancer research.

[13]  Meng Yang,et al.  Subcellular imaging in the live mouse , 2006, Nature Protocols.

[14]  D. Burggraf,et al.  Matrix metalloproteinase‐9 promotes neutrophil and T cell recruitment and migration in the postischemic liver , 2006, Journal of leukocyte biology.

[15]  R. Kucherlapati,et al.  Peroxisome proliferator‐activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/− double mutant mice , 2005, International journal of cancer.

[16]  Kuniyoshi Tanaka,et al.  Intermittent hepatic ischemia-reperfusion minimizes liver metastasis in rats. , 2003, The Journal of surgical research.

[17]  H. Nakagama,et al.  Peroxisome proliferator-activated receptor gamma ligands suppress colon carcinogenesis induced by azoxymethane in mice. , 2003, Gastroenterology.

[18]  T. Osawa,et al.  Protective effects of dietary cyanidin 3-O-beta-D-glucoside on liver ischemia-reperfusion injury in rats. , 1999, Archives of biochemistry and biophysics.

[19]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[20]  J. Auwerx,et al.  Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/+ mice , 1998, Nature Medicine.

[21]  J. G. Alvarez,et al.  Activators of the nuclear receptor PPARγ enhance colon polyp formation , 1998, Nature Medicine.

[22]  N. Yamamoto,et al.  PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model , 2019, Cancer Genomics & Proteomics.

[23]  E. Soliman,et al.  PPAR gamma agonist, pioglitazone, rescues liver damage induced by renal ischemia/reperfusion injury , 2019, Toxicology and applied pharmacology.

[24]  J. Seo,et al.  PPAR-gamma ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo. , 2008, Investigational new drugs.